

Title (en)  
DIHYDROPYRIDINES

Publication  
**EP 0106462 A3 19840530 (EN)**

Application  
**EP 83304954 A 19830826**

Priority  
GB 8225246 A 19820904

Abstract (en)

[origin: EP0106462A2] 1,4-Dihydropyridine derivatives of the formula:-and their pharmaceutically acceptable acid addition salts; where R is aryl or heteroaryl; R<sup>1</sup> and R<sup>2</sup> are each independently C<sub>1</sub>-C<sub>4</sub> alkyl or 2-methoxyethyl; Y is -(CH<sub>2</sub>)<sub>2</sub>-, -(CH<sub>2</sub>)<sub>3</sub>-, -CH<sub>2</sub>CH(CH<sub>3</sub>)- or -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-; R<sup>3</sup> is hydrogen or a group selected from: where R<sup>4</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CH<sub>2</sub>COO(C<sub>1</sub>-C<sub>4</sub> alkyl), aryl, -SO<sub>2</sub>aryl, or heteroaryl, and X is O or S; where R<sup>5</sup> is 1-pyrrolidinyl, -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>, or -NH(CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub>); where R<sup>6</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl or aryl; where R<sup>7</sup> is -CONH(C<sub>1</sub>-C<sub>4</sub> alkyl) or -COO(C<sub>1</sub>-C<sub>4</sub> alkyl); where R<sup>8</sup> is -CN, -SO<sub>2</sub>C<sub>1</sub>-C<sub>4</sub> alkyl or -SO<sub>2</sub>aryl; (h) -CH<sub>2</sub>CO<sub>2</sub>R<sup>9</sup> where R<sup>9</sup> is -NH<sub>2</sub>, -NH(C<sub>1</sub>-C<sub>4</sub> alkyl), -NH<sub>2</sub> or C<sub>1</sub>-C<sub>4</sub> alkoxy; (i) -SO<sub>2</sub>R<sup>10</sup> where R<sup>10</sup> is -NH<sub>2</sub>, -N(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>2</sub> or C<sub>1</sub>-C<sub>4</sub> alkyl; and (j) -CO<sub>2</sub>R where R is H, halomethyl, -COO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CH<sub>2</sub>CO(C<sub>1</sub>-C<sub>4</sub> alkyl), -CH<sub>2</sub>CO(C<sub>1</sub>-C<sub>4</sub> alkyl), C<sub>1</sub>-C<sub>4</sub> alkoxy, aryl, heteroaryl, morpholino or 5-oxo-pyrrolidin-2-yl. The compounds have utility as anti-ischaemic and antihypertensive agents.

IPC 1-7  
**C07D 211/90**; **C07D 401/12**; **C07D 407/12**; **C07D 417/12**; **A61K 31/445**

IPC 8 full level  
**C07D 295/08** (2006.01); **A61K 31/4422** (2006.01); **A61K 31/4427** (2006.01); **A61K 31/443** (2006.01); **A61K 31/445** (2006.01); **A61K 31/455** (2006.01); **A61K 31/495** (2006.01); **A61K 31/535** (2006.01); **A61K 31/5375** (2006.01); **A61P 3/00** (2006.01); **A61P 9/06** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **C07D 211/84** (2006.01); **C07D 211/90** (2006.01); **C07D 295/088** (2006.01); **C07D 295/14** (2006.01); **C07D 401/02** (2006.01); **C07D 401/12** (2006.01); **C07D 405/12** (2006.01); **C07D 407/12** (2006.01); **C07D 417/04** (2006.01); **C07D 417/12** (2006.01)

CPC (source: EP KR US)  
**A61P 3/00** (2017.12 - EP); **A61P 9/06** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **C07D 211/90** (2013.01 - EP US); **C07D 295/088** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP KR US); **C07D 407/12** (2013.01 - EP US); **C07D 417/12** (2013.01 - EP US)

Citation (search report)  
• [YPD] EP 0060674 A1 19820922 - PFIZER LTD [GB], et al  
• [Y] DERWENT JAPANESE PATENTS, Section Chemical, vol. 4, no. 85 (C-15)(567), June 18, 1980, page 3 C 15, Derwent Publications Ltd. & JP-A-55 047 656 (DAINIPPON SEIYAKU K.K.) 04-04-1980

Cited by  
EP0711554A4; EP0278642A3; EP0172029A1; EP0132375A3; EP0959887A4; EP0250725A1; US4757080A; GB2163050B; US4900750A; EP0254064A1; US5047414A; FR2829766A1; EP0294074A1; EP0222598A3; EP0165032A3; WO03024946A3; WO2022175384A1; WO8800187A1; EP0255075B1

Designated contracting state (EPC)  
AT BE CH DE FR GB IT LI LU NL SE

DOCDB simple family (publication)  
**EP 0106462 A2 19840425**; **EP 0106462 A3 19840530**; **EP 0106462 B1 19881207**; AT E39112 T1 19881215; AU 1865883 A 19840308; AU 542454 B2 19850221; CA 1205470 A 19860603; CS 242881 B2 19860515; CS 639583 A2 19850815; DD 215544 A5 19841114; DE 3378632 D1 19890112; DK 161700 B 19910805; DK 161700 C 19920106; DK 398383 A 19840305; DK 398383 D0 19830901; ES 525241 A0 19860116; ES 532038 A0 19851201; ES 8602760 A1 19851201; ES 8604200 A1 19860116; FI 80262 B 19900131; FI 80262 C 19900510; FI 833117 A0 19830901; FI 833117 A 19840305; GR 78985 B 19841002; HU 191092 B 19870128; IE 55904 B1 19910214; IE 832058 L 19840304; IL 69627 A0 19831230; IL 69627 A 19860831; JP S5980663 A 19840510; JP S6222985 B2 19870520; KR 840006236 A 19841122; KR 880000180 B1 19880312; NO 160259 B 19881219; NO 160259 C 19890329; NO 833159 L 19840305; NZ 205472 A 19850816; PH 19166 A 19860116; PL 139499 B1 19870131; PL 143900 B1 19880331; PL 243621 A1 19850507; PL 250618 A1 19850730; PT 77283 A 19831001; PT 77283 B 19860519; SU 1364237 A3 19871230; SU 1378782 A3 19880228; US 4539322 A 19850903; YU 178583 A 19861031; YU 179985 A 19861031; YU 43598 B 19890831; YU 43659 B 19891031; ZA 836514 B 19840725

DOCDB simple family (application)  
**EP 83304954 A 19830826**; AT 83304954 T 19830826; AU 1865883 A 19830902; CA 435935 A 19830902; CS 639583 A 19830902; DD 25448683 A 19830902; DE 3378632 T 19830826; DK 398383 A 19830901; ES 525241 A 19830830; ES 532038 A 19840430; FI 833117 A 19830901; GR 830172365 A 19830902; HU 307783 A 19830902; IE 205883 A 19830901; IL 6962783 A 19830902; JP 16310383 A 19830905; KR 830004157 A 19830903; NO 833159 A 19830902; NZ 20547283 A 19830902; PH 29436 A 19830824; PL 24362183 A 19830902; PL 25061883 A 19830902; PT 7728383 A 19830902; SU 3641411 A 19830902; SU 3750492 A 19840611; US 52850783 A 19830901; YU 178583 A 19830901; YU 179985 A 19851119; ZA 836514 A 19830902